Header Logo

Changmeng Cai PhD

TitleAdjunct Associate Professor
InstitutionUMass Chan Medical School
DepartmentMedicine
AddressUniversity of Massachusetts Boston
100 William T Morrissey Blvd
Boston MA 02125-3300
Phone617-287-3537
vCardDownload vCard
    Other Positions
    InstitutionT.H. Chan School of Medicine
    DepartmentMedicine


    Collapse Biography 
    Collapse education and training
    Tsinghua University, Beijing, , ChinaBSBiomedical Engineering
    University of Toledo, Toledo, OH, United StatesMSBioengineering
    University of Toledo, Toledo, OH, United StatesPHDBiological Sciences

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Jamroze A, Liu X, Hou S, Jess Li W, Yu H, Tracz A, Jacobi J, Li Q, Nastiuk K, Chen X, Huang J, Lin K, Liu M, Cai C, Lu Y, Puzanov I, Kirk JS, Chatta G, Tang DG. Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. Signal Transduct Target Ther. 2026 May 01; 11(1). PMID: 42067541.
      Citations:    
    2. Ma F, Chen S, Cecchi L, Ersoy-Fazlioglu B, Russo JW, Arai S, Awad S, Calagua C, Xie F, Poluben L, Voznesensky O, Ku AT, Karzai F, Cai C, Einstein DJ, Ye H, Yuan X, Toker A, Taplin ME, Sowalsky AG, Balk SP. Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion. J Clin Invest. 2025 12 01; 135(23). PMID: 41321318.
      Citations:    
    3. Ma F, Chen S, Cecchi L, Ersoy-Fazlioglu B, Russo J, Arai S, Awad S, Calagua C, Xie F, Poluben L, Voznesensky O, Ku A, Karzai F, Cai C, Einstein D, Ye H, Yuan X, Toker A, Taplin ME, Sowalsky AG, Balk S. Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion. bioRxiv. 2025 Jul 22. PMID: 40777361.
      Citations:    
    4. Gao S, Patten ND, Cai C. Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance. J Natl Cancer Cent. 2026 Feb; 6(1):58-72. PMID: 41738032.
      Citations:    
    5. Labaf M, Han W, Zhang S, Liu M, Patten ND, Li M, Patalano S, Macoska JA, Balk SP, Han D, Zarringhalam K, Cai C. Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells. Mol Cancer Ther. 2025 May 02; 24(5):772-783. PMID: 40116305.
      Citations:    
    6. Berger N, Kugler B, Han D, Li M, Nguyen P, Anderson M, Patalano-Salsman S, Zhang S, Macoska J, Cai C, Zou K. Voluntary Exercise Attenuates Tumor Growth in a Preclinical Model of Castration-Resistant Prostate Cancer. Med Sci Sports Exerc. 2025 Aug 01; 57(8):1732-1742. PMID: 40173332.
      Citations:    
    7. Berger N, Kugler B, Han D, Li M, Nguyen P, Anderson M, Zhang S, Cai C, Zou K. Voluntary Exercise Attenuates Tumor Growth in a Preclinical Model of Castration-Resistant Prostate Cancer. bioRxiv. 2024 Oct 18. PMID: 39464116.
      Citations:    
    8. Wang Z, Townley SL, Zhang S, Liu M, Li M, Labaf M, Patalano S, Venkataramani K, Siegfried KR, Macoska JA, Han D, Gao S, Risbridger GP, Taylor RA, Lawrence MG, He HH, Selth LA, Cai C. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. Nat Commun. 2024 Jun 08; 15(1):4914. PMID: 38851846.
      Citations:    
    9. Han D, Labaf M, Zhao Y, Owiredu J, Zhang S, Patel K, Venkataramani K, Steinfeld JS, Han W, Li M, Liu M, Wang Z, Besschetnova A, Patalano S, Mulhearn MJ, Macoska JA, Yuan X, Balk SP, Nelson PS, Plymate SR, Gao S, Siegfried KR, Liu R, Stangis MM, Foxa G, Czernik PJ, Williams BO, Zarringhalam K, Li X, Cai C. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs. J Clin Invest. 2024 Apr 30; 134(11). PMID: 38687617.
      Citations:    
    10. Besschetnova A, Han W, Liu M, Gao Y, Li M, Wang Z, Labaf M, Patalano S, Venkataramani K, Muriph RE, Macoska JA, Siegfried KR, Evans J, Balk SP, Gao S, Han D, Cai C. Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression. Cancer Res Commun. 2023 08; 3(8):1716-1730. PMID: 37663929.
      Citations:    
    11. Wang Z, Petricca J, Liu M, Zhang S, Chen S, Li M, Besschetnova A, Patalano S, Venkataramani K, Siegfried KR, Macoska JA, Han D, Gao S, Vedadi M, Arrowsmith CH, He HH, Cai C. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Proc Natl Acad Sci U S A. 2023 08 15; 120(33):e2220472120. PMID: 37549269.
      Citations:    
    12. Li M, Liu M, Han W, Wang Z, Han D, Patalano S, Macoska JA, Balk SP, He HH, Corey E, Gao S, Cai C. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer. Cancer Res. 2023 05 15; 83(10):1684-1698. PMID: 36877164.
      Citations:    
    13. Labaf M, Li M, Ting L, Karno B, Zhang S, Gao S, Patalano S, Macoska JA, Zarringhalam K, Han D, Cai C. Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2. Front Oncol. 2022; 12:1021845. PMID: 36408179.
      Citations:    
    14. Han W, Liu M, Han D, Toure AA, Li M, Besschetnova A, Wang Z, Patalano S, Macoska JA, Lam HM, Corey E, He HH, Gao S, Balk SP, Cai C. Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Mol Ther. 2022 04 06; 30(4):1628-1644. PMID: 35121110.
      Citations:    
    15. Liao Y, Chen CH, Xiao T, de la Pe?a Avalos B, Dray EV, Cai C, Gao S, Shah N, Zhang Z, Feit A, Xue P, Liu Z, Yang M, Lee JH, Xu H, Li W, Mei S, Pierre RS, Shu S, Fei T, Duarte M, Zhao J, Bradner JE, Polyak K, Kantoff PW, Long H, Balk SP, Liu XS, Brown M, Xu K. Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proc Natl Acad Sci U S A. 2022 01 18; 119(3). PMID: 35031563.
      Citations:    
    16. Han W, Liu M, Han D, Li M, Toure AA, Wang Z, Besschetnova A, Patalano S, Macoska JA, Gao S, He HH, Cai C. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. Oncogene. 2022 Feb; 41(6):852-864. PMID: 34975152.
      Citations:    
    17. Han D, Owiredu JN, Healy BM, Li M, Labaf M, Steinfeld JS, Patalano S, Gao S, Liu M, Macoska JA, Zarringhalam K, Siegfried KR, Yuan X, Rebbeck TR, Cai C. Susceptibility-Associated Genetic Variation in NEDD9 Contributes to Prostate Cancer Initiation and Progression. Cancer Res. 2021 07 15; 81(14):3766-3776. PMID: 33632899.
      Citations:    
    18. Teng M, Zhou S, Cai C, Lupien M, He HH. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell. 2021 01; 12(1):29-38. PMID: 32946061.
      Citations:    
    19. Gao S, Chen S, Han D, Wang Z, Li M, Han W, Besschetnova A, Liu M, Zhou F, Barrett D, Luong MP, Owiredu J, Liang Y, Ahmed M, Petricca J, Patalano S, Macoska JA, Corey E, Chen S, Balk SP, He HH, Cai C. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet. 2020 10; 52(10):1011-1017. PMID: 32868907.
      Citations:    
    20. Cai C. A Novel Mechanism to Induce BRCAness in Cancer Cells. Cancer Res. 2020 07 15; 80(14):2977-2978. PMID: 32669350.
      Citations:    
    21. Han D, Chen S, Han W, Gao S, Owiredu JN, Li M, Balk SP, He HH, Cai C. ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. Cancer Res. 2019 10 15; 79(20):5260-5271. PMID: 31444154.
      Citations:    
    22. Wang Z, Gao S, Han D, Han W, Li M, Cai C. LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells. Front Oncol. 2019; 9:721. PMID: 31428587.
      Citations:    
    23. Gao S, Chen S, Han D, Barrett D, Han W, Ahmed M, Patalano S, Macoska JA, He HH, Cai C. Forkhead domain mutations in FOXA1 drive prostate cancer progression. Cell Res. 2019 Sep; 29(9):770-772. PMID: 31324883.
      Citations:    
    24. Zhou F, Gao S, Han D, Han W, Chen S, Patalano S, Macoska JA, He HH, Cai C. TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells. Oncogene. 2019 05; 38(22):4397-4411. PMID: 30718921.
      Citations:    
    25. Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SP. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res. 2018 09 15; 78(18):5203-5215. PMID: 30012673.
      Citations:    
    26. Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng FY, Joshua AM, Zoubeidi A, Cai C, He HH. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Res. 2017 10 15; 77(20):5479-5490. PMID: 28916652.
      Citations:    
    27. Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA. Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Mol Cancer Res. 2017 05; 15(5):521-531. PMID: 28465296.
      Citations:    
    28. Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y, Zhang T, Russo J, Cai C, Yuan X, Liu J, Chen S, Balk SP. Positive feedback loop mediated by protein phosphatase 1a mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Res. 2017 04 20; 45(7):3738-3751. PMID: 28062857.
      Citations:    
    29. Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. Oncotarget. 2017 Jan 24; 8(4):6796-6808. PMID: 28036278.
      Citations:    
    30. Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP, Cai C. Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Rep. 2016 10 18; 17(4):966-976. PMID: 27760327.
      Citations:    
    31. Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan X. SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 2016 05 02; 126(5):1745-58. PMID: 27043282.
      Citations:    
    32. Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 07 15; 22(14):3672-82. PMID: 26936914.
      Citations:    
    33. Liu X, Han W, Gulla S, Simon NI, Gao Y, Cai C, Yang H, Zhang X, Liu J, Balk SP, Chen S. Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget. 2016 Jan 12; 7(2):1754-64. PMID: 26636645.
      Citations:    
    34. Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15; 75(10):1944-8. PMID: 25808865.
      Citations:    
    35. Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, Chen S, Chen MW, Zhang J, Ahmed M, Wang Y, Metzger E, Sch?le R, Liu XS, Brown M, Balk SP. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 2014 Dec 11; 9(5):1618-1627. PMID: 25482560.
      Citations:    
    36. Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80. PMID: 25320358.
      Citations:    
    37. Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res. 2014 Aug 01; 20(15):4075-85. PMID: 24874833.
      Citations:    
    38. Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014 Mar 15; 20(6):1590-600. PMID: 24449822.
      Citations:    
    39. Cai C, Yuan X, Balk SP. Androgen receptor epigenetics. Transl Androl Urol. 2013 Sep 01; 2(3):148-157. PMID: 25580383.
      Citations:    
    40. Chen S, Jiang X, Gewinner CA, Asara JM, Simon NI, Cai C, Cantley LC, Balk SP. Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal. 2013 May 28; 6(277):ra40. PMID: 23716717.
      Citations:    
    41. Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP, Liu Q, Gray NS. Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol. 2013 Jul 19; 8(7):1423-8. PMID: 23594111.
      Citations:    
    42. Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013 Mar; 123(3):1109-22. PMID: 23426182.
      Citations:    
    43. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012 Dec 14; 338(6113):1465-9. PMID: 23239736.
      Citations:    
    44. Shen HC, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, Balk SP, Rigby AC. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Mol Endocrinol. 2012 Nov; 26(11):1836-46. PMID: 23023563.
      Citations:    
    45. Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem. 2012 Mar 09; 287(11):8571-83. PMID: 22275373.
      Citations:    
    46. Cai C, Hsieh CL, Gao S, Kannan A, Bhansali M, Govardhan K, Dutta R, Shemshedini L. Soluble guanylyl cyclase a1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer. Mol Endocrinol. 2012 Feb; 26(2):292-307. PMID: 22174378.
      Citations:    
    47. Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP, Yuan X. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. J Biol Chem. 2012 Jan 13; 287(3):2090-8. PMID: 22139837.
      Citations:    
    48. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011 Oct 18; 20(4):457-71. PMID: 22014572.
      Citations:    
    49. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011 Oct; 18(5):R175-82. PMID: 21712345.
      Citations:    
    50. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011 Oct 15; 71(20):6503-13. PMID: 21868758.
      Citations:    
    51. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009 Aug 01; 69(15):6027-32. PMID: 19584279.
      Citations:    
    52. Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res. 2009 Jun 15; 69(12):5202-9. PMID: 19491261.
      Citations:    
    53. Hsieh CL, Cai C, Giwa A, Bivins A, Chen SY, Sabry D, Govardhan K, Shemshedini L. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells. J Mol Endocrinol. 2008 Jul; 41(1):13-23. PMID: 18469090.
      Citations:    
    54. Cai C, Hsieh CL, Shemshedini L. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Mol Cancer Res. 2007 Jul; 5(7):725-35. PMID: 17634427.
      Citations:    
    55. Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol. 2007 Aug; 21(8):1835-46. PMID: 17505060.
      Citations:    
    56. Omwancha J, Zhou XF, Chen SY, Baslan T, Fisher CJ, Zheng Z, Cai C, Shemshedini L. Makorin RING finger protein 1 (MKRN1) has negative and positive effects on RNA polymerase II-dependent transcription. Endocrine. 2006 Apr; 29(2):363-73. PMID: 16785614.
      Citations:    
    57. Zheng Z, Cai C, Omwancha J, Chen SY, Baslan T, Shemshedini L. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. J Biol Chem. 2006 Feb 17; 281(7):4002-12. PMID: 16361251.
      Citations:    
    Cai's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (273)
    Explore
    _
    Co-Authors (2)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _